MAPT and Atrophy: Nevertheless, future studies should exclude any influence of early-onset AD though comprehensive analysis such as neuroimaging to detect widespread cortical atrophy, in particular parietal lobe atrophy [34], as well as laboratory analysis of biomarkers and positron emission tomography to detect amyloid and tau aggregates.